- HER2 negative
- ER positive
- PD-L1 positive
- PR positive
- ER negative
- HER2 positive
- PD-L1 negative
- PR negative
- BRAF positive
- EGFR negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Adjuvant Therapy (except reconstruction)
- Anthracycline
- Anti-HER2 Therapy
- At least one prior tumor-directed therapy
- Biologic Anti-Neoplastic Agent
- Cancer-Directed Surgery
- Carboplatin
- Endocrine Therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
1116 trials
Trials Without a Placebo
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial uses knee injections called RTX-GRT7039 for patients with knee osteoarthritis who still have pain despite usual treatments. The injections aim to reduce knee pain, possibly by affecting pain pathways or inflammation.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Knoxville, TN (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if a daily pill called upadacitinib can help people with a painful skin condition called hidradenitis suppurativa (HS) who haven't responded to usual treatments. The study will involve adults and teenagers and will check for safety and effectiveness over time. Participants will be randomly given either the medication or a non-active pill, and their progress will be monitored through periodic medical check-ups.
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<10 mi)
Recruiting
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial program provides families with knowledge about healthy eating and activity, as well as vouchers to buy fresh fruits and vegetables from a local retail store.
Efficacy & Safety Awards
No Placebo-Only Group
Knoxville, TN (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called fianlimab with cemiplimab and chemotherapy in patients with advanced lung cancer. The goal is to see if this combination is more effective than current treatments. The new drugs help the immune system fight cancer, while chemotherapy attacks the cancer cells directly.
Knoxville, TN (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug combination for patients with advanced lung cancer. It aims to see if using two drugs together is more effective than one alone. The study also looks at side effects, how the drugs are processed in the body, and their impact on quality of life.
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a new drug combination for adults with advanced NSCLC without specific genetic mutations. The treatment includes Dato-DXd, durvalumab, and carboplatin, which work together to kill cancer cells, boost the immune system, and stop cancer cell growth.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Rhabdomyosarcoma trials are postedWe'll send you an email whenever new trials are posted
Knoxville, TN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial uses chemotherapy drugs to treat patients with very low-risk and low-risk rhabdomyosarcoma. The goal is to maintain good outcomes while reducing treatment intensity. The study also examines if patients with specific DNA mutations benefit from more intensive therapy.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares the effect of open thoracic surgery to thoracoscopic surgery in treating patients with osteosarcoma that has spread to the lung.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new cancer treatment for patients with high risk rhabdomyosarcoma. The treatment is a combination of 4 drugs, and the trial will test if it is more effective than the current standard of care.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether a new combination therapy is better than the current standard of care for treating a certain type of breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone to see how well they work in treating PMBCL.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is investigating whether adding vinblastine to selumetinib improves treatment of recurrent or progressive low-grade glioma in children and young adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will compare the effects of sacituzumab govitecan-hziy versus TPC on overall survival in people with advanced UC.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is investigating whether a combination of navitoclax and ruxolitinib is more effective and safe in assessment of change in spleen volume when compared to ruxolitinib in participants with myelofibrosis.
Efficacy & Safety Awards
Pivotal Trial
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Acute Myeloid Leukemia trials are postedWe'll send you an email whenever new trials are posted
Knoxville, TN (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether a new combination of drugs (CPX-351 and gilteritinib) is more effective than standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Knoxville, TN (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new cancer treatment that may be more effective and have fewer side effects than the current standard of care.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50